Skip to content
Screener

Omeros OMER Current ratio

Current ratio at other companies

Immunome logo
ImmunomeIMNM
21.7×+11.2×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
8.4×-1.4×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×
Annexon logo
AnnexonANNX
6.4×-1.6×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
9.4×+5.2×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×

Where this comes from

Calculated from Omeros’s reported figures.

Based on the most recent quarter.

The source filing: Omeros’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 4:07 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001437749-26-016720

FAQ

What is Omeros's current ratio?
Omeros (OMER) reported current ratio of 3× in Q1 2026.
How has Omeros's current ratio changed year-over-year?
Omeros's current ratio increased by 162.5% year-over-year, from 1.2× to 3×.
What is the long-term trend for Omeros's current ratio?
Over 5 years (2020 to 2025), Omeros's current ratio has grown at a -7.7% compound annual growth rate (CAGR), from 4.1× to 2.8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Omeros's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude